Table 1 Summary statistics of the cohort, stratified by the FISH results of F. nucleatum. The continuous variables and categorical variables were respectively presented as median (IQR) and number (percentage %) among all patients or patients in each subgroup
Variables | All patients (n = 304) | FISH of F. nucleatum | P value | |
|---|---|---|---|---|
Positive (n = 105) | Negative (n = 199) | |||
Age, years | 64.00(14.00) | 61.00(15.00) | 66.00(13.00) | 0.000 |
Sex, male | 224(73.68%) | 73(69.52%) | 151(75.88%) | 0.231 |
BMI, Obese | 34(11.18%) | 9(8.57%) | 25(12.56%) | 0.294 |
Smoker | 122(40.13%) | 41(39.05%) | 81(40.70%) | 0.779 |
HTN, Yes | 75(24.67%) | 31(29.52%) | 44(22.11%) | 0.154 |
DM, Yes | 34(11.18%) | 12(11.43%) | 22(11.06%) | 0.922 |
CVD, Yes | 65(21.38%) | 21(20.00%) | 44(22.11%) | 0.670 |
Histology, Adenocarcinoma | 282(92.76%) | 96(91.43%) | 186(93.47%) | 0.514 |
Sites of cancer | ||||
Cardia or fundus | 194(63.82%) | 63(60.00%) | 131(65.83%) | 0.372 |
Corpus | 45(14.80%) | 14(13.33%) | 31(15.58%) | - |
Antrum or pylorus | 51(16.78%) | 23(21.90%) | 28(14.07%) | - |
Multiple sites | 14(4.61%) | 5(4.76%) | 9(4.52%) | - |
Stages, IV stage | 101(33.22%) | 47(44.76%) | 54(27.14%) | 0.002 |
Treatment | ||||
Chemotherapy only | 64(21.05%) | 31(29.52%) | 33(16.58%) | 0.073 |
Combined surgery | 218(71.71%) | 67(63.81%) | 151(75.88%) | - |
Combined radiation | 12(3.95%) | 4(3.81%) | 8(4.02%) | - |
Combined surgery and radiation | 10(3.29%) | 3(2.86%) | 7(3.52%) | - |
CVC, Yes | 140(46.05%) | 46(43.81%) | 94(47.24%) | 0.569 |
Targeted drug, Yes | 55(18.15%) | 28(26.67%) | 27(13.64%) | 0.005 |
PD-1, Yes | 14(4.61%) | 6(5.71%) | 8(4.02%) | 0.568 |
Disease status at the time of VTE diagnosis | ||||
During 3-wk postoperative period | 54(17.76%) | 9(8.57%) | 45(22.61%) | 0.004 |
During four cycles chemotherapy | 94(30.92%) | 43(40.95%) | 51(25.63%) | - |
During both period | 14(4.61%) | 5(4.76%) | 9(4.52%) | - |
Neither | 142(46.71%) | 48(45.71%) | 94(47.24%) | - |
Sites of VTE | ||||
DVT | 191(62.83%) | 36(34.29%) | 155(77.89%) | 0.000 |
SVT | 54(17.76%) | 49(46.67%) | 5(2.51%) | - |
PE | 22(7.24%) | 11(10.48%) | 11(5.53%) | - |
Catheter-related thrombosis | 37(12.17%) | 9(8.57%) | 28(14.07%) | - |
Time to VTE diagnosis, months | 2.22(5.49) | 3.10(5.57) | 1.63(4.33) | 0.033 |
Antithrombotic therapy | ||||
LMWH | 155(50.99%) | 55(52.38%) | 100(50.25%) | 0.984 |
DOACs | 117(38.49%) | 40(38.10%) | 77(38.69%) | - |
Thrombolysis | 7(2.30%) | 2(1.90%) | 5(2.51%) | - |
IVC filter | 25(8.22%) | 8(7.62%) | 17(8.54%) | - |
Hemorrhage, Yes | 25(8.22%) | 8(7.62%) | 17(8.54%) | 0.780 |
KRS, High risk | 120(39.47%) | 49(46.67%) | 71(35.68%) | 0.062 |
ECOG, ≥ 1 | 139(45.72%) | 56(53.33%) | 83(41.71%) | 0.053 |
CEA, ng/ml | 3.84(6.47) | 3.92(6.68) | 3.70(5.71) | 0.328 |
CA199, u/ml | 14.88(23.71) | 15.90(28.50) | 14.07(20.48) | 0.117 |
CA724, u/ml | 3.03(8.39) | 5.75(15.70) | 2.08(5.55) | 0.000 |
Hemoglobin, g/L | 109.00(22.00) | 106.00(25.00) | 111.00(18.50) | 0.001 |
Albumin, g/L | 37.50(6.98) | 36.60(7.70) | 37.90(6.70) | 0.061 |
Platelet, × 109/L | 168.00(99.50) | 184.00(98.00) | 159.50(82.50) | 0.010 |
Leucocyte, × 109/L | 5.22(3.77) | 4.73(3.23) | 5.35(4.09) | 0.061 |
Neutrophil, × 109/L | 3.16(3.31) | 3.29(2.67) | 3.10(3.81) | 0.850 |
Lymphocyte, × 109/L | 1.29(0.83) | 1.04(0.60) | 1.47(0.91) | 0.000 |
Fibrinogen, g/L | 2.69(1.07) | 2.85(1.14) | 2.62(0.99) | 0.019 |
D-dimer, mg/L | 1.63(3.28) | 1.92(3.63) | 1.52(3.02) | 0.585 |
NLR | 2.45(3.64) | 3.49(3.47) | 2.07(3.14) | 0.001 |
PLR | 123.70(112.45) | 190.34(132.37) | 109.65(72.91) | 0.000 |